About this episode
Hey, listeners! In a groundbreaking study featured in Neuro-oncology, the FDA-approved drug vorasidenib is making waves in the fight against IDH-mutant gliomas, the most common malignant brain tumors in young adults. This breakthrough provides a new hope with its ability to penetrate the brain and target mutant IDH1/2 proteins, potentially delaying the progression of these tumors and reducing reliance on aggressive therapies that impact quality of life. Tune in as we dive into the future of glioma treatment with vorasidenib and its promising clinical trials.
Get every episode summarized
Each time 萌喵读文献-神经病学 publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
